特拉华州威尔明顿的。，Feb. 3, 2021 /PRNewswire/ -- DuPont (NYSE: DD) announced today the final results of its exchange offer, and the final proration factor of 52.5307455 percent, in connection with the previously announced separation of its nutrition and biosciences business (the "N&B Business") and merger of Nutrition & Biosciences, Inc. ("N&B"), a DuPont subsidiary formed to hold the N&B Business, with a subsidiary of International Flavors & Fragrances Inc. ("IFF") (NYSE: IFF).
共有368,655,051股杜邦股票股票在交易所报价中有效招标（且未撤回），其中由股东招标的7,905,588股股份，他们有资格获得奇怪的待遇。此类奇数股东不受普罗金目，而股票在交易所报价中完全被接受。使用最终奖金因子，在职业额度基础上，在“职业比例”基础上接受了违约股份的剩余股票股票。有效招标但不接受汇款的杜邦股票股票将返回招标股东。
根据交换要约的条款，141,740,461股N&B普通股可供分配，以交换要约中接受的杜邦普通股。此次换股要约的最终换股比例为0.7180股N&B普通股换一股有效投标且未适当撤回的杜邦普通股。合并后，每一股N&B普通股自动转换为获得一股IFF普通股的权利。因此，作为交换要约的一部分，将杜邦普通股股份作为交换要约的一部分进行投标的杜邦股东，每接受一股杜邦普通股作为交换要约的一部分，将获得0.7180股IFF普通股(以现金代替零星股份为条件)。杜邦在收购要约中接受了197,410113股杜邦普通股，相当于其截至2021年1月29日发行股票的约27%。
在此次交易中，高盛(Goldman Sachs)、摩根大通(J.P. Morgan)和Evercore担任杜邦的财务顾问，世达律师事务所(Skadden, Arps, Slate, Meagher & Flom)担任法律顾问。
2/3/21
Dupont™，Dupont椭圆徽标以及用™表示的所有商标和服务标记，SM或者®除非另有说明，否则由Dupont de Nemours，Inc的附属公司拥有。
对杜邦公司
杜邦公司(NYSE: DD)是全球创新领导者，以技术为基础的材料和解决方案帮助改变行业和日常生活。我们的员工运用不同的科学和专业知识，帮助客户在电子、交通、建筑、水、医疗和工人安全等关键市场推进他们的最佳理念，并提供必要的创新。有关该公司、其业务和解决方案的更多信息，请访问www.ljlcyg.com．投资者可访问网站投资者关系部分的信息，网址为investors.dupont.com．
关于前瞻性陈述的注意事项
该沟通在联邦证券法中的含义内包含“前瞻性陈述”，包括“证券法”第27A条，1934年“修订”（“交流法”）的“证券交易法”第21E条。在这种情况下，前瞻性陈述往往地满足预期的未来业务和财务绩效以及财务状况，通常包含“期待”等词语，“预期”，“打算”，“计划，”“求人”，“求，”“请参阅”，“”将“，”将“，”目标，“类似的表达式，以及这些词的变化或否定。他们的自然地址的前瞻性陈述是对不同程度，不确定的事项，如关于交易的陈述，交易的好处和协同作用，联合公司和产品的未来机会，建议的组织和运营的好处合并公司的型号和关于杜邦，IFF和N＆B的未来业务，财务或经营业绩，资本配置，股息政策，债务比率，预期业务水平，未来盈利，计划活动，预期增长，市场机会，策略，竞争以及未来时期的其他期望和目标。有几个因素可能导致实际计划和结果与前瞻性陈述中表达或暗示的人不同。这些因素包括但不限于（1）缔约方能够满足关于交易会计和税收处理的预期的能力，（2）相关税和其他法律的变化，（3）不可预见负债的可能性，未来资本支出，收入，费用，盈利，协同作用，经济绩效，债务，财务状况，损失，可能影响交易价值的未来前景，业务和管理战略，（4）与Corteva分配有关的风险和费用2019年6月1日（“Corteva Distribution”）和Dow Inc.的分销2019年4月1日（“Dow Distribution”和Corteva分配“以前的分布”），包括某些遗产负债的赔偿 of E. I. du Pont de Nemours and Company ("Historical EID"), a subsidiary of Corteva, in connection with the Corteva Distribution and potential liability arising from fraudulent conveyance and similar laws in connection with the Previous Distributions, (5) risks and costs related to the performance under and impact of the cost sharing arrangement by and between DuPont, Corteva, Inc. and The Chemours Company related to future eligible PFAS liabilities, (6) failure to effectively manage acquisitions, divestitures, alliances, joint ventures and other portfolio changes, including meeting conditions under the Letter Agreement entered in connection with the Corteva Distribution, related to the transfer of certain levels of assets and businesses, (7) uncertainty as to the long-term value of DuPont common stock, (8) potential inability or reduced access to the capital markets or increased cost of borrowings, including as a result of a credit rating downgrade, (9) inherent uncertainties involved in the estimates and judgments used in the preparation of financial statements and the providing of estimates of financial measures, in accordance with the accounting principles generally accepted in the United States of America and related standards, or on an adjusted basis, (10) the integration of IFF and its Frutarom business and/or N&B being more difficult, time consuming or costly than expected, (11) the failure to achieve expected or targeted future financial and operating performance and results, (12) the possibility that IFF may be unable to achieve expected benefits, synergies and operating efficiencies in connection with the transaction within the expected time frames or at all or to successfully integrate Frutarom and N&B, (13) customer loss and business disruption being greater than expected following the transaction, (14) legislative, regulatory and economic developments; (15) an increase or decrease in the anticipated transaction taxes (including due to any changes to tax legislation and its impact on tax rates (and the timing of the effectiveness of any such changes)), (16) potential litigation relating to the transaction that could be instituted against DuPont, IFF or their respective directors, (17) risks associated with third party contracts containing consent and/or other provisions that may be triggered by the transaction, (18) negative effects of the consummation of the transaction on the market price of DuPont's and/or IFF's common stock, (19) risks relating to the value of the IFF shares to be issued in the transaction and uncertainty as to the long-term value of IFF's common stock, (20) the impact of the failure to comply with U.S. or foreign anti-corruption and anti-bribery laws and regulations, (21) the ability of N&B or IFF to retain and hire key personnel, (26) the risk that N&B and IFF will incur significant indebtedness in connection with the transaction, and the degree to which IFF will be leveraged following completion of the transaction may materially and adversely affect its business, financial condition and results of operations, (23) that N&B may not achieve certain targeted cost and productivity improvements, which could adversely impact its results of operations and financial condition, and (24) other risks to DuPont's, N&B's and IFF's business, operations and results of operations including from: failure to develop and market new products and optimally manage product life cycles; ability, cost and impact on business operations, including the supply chain, of responding to changes in market acceptance, rules, regulations and policies and failure to respond to such changes; outcome of significant litigation, environmental matters and other commitments and contingencies; failure to appropriately manage process safety and product stewardship issues; global economic and capital market conditions, including the continued availability of capital and financing, as well as inflation, interest and currency exchange rates; changes in political conditions, including tariffs, trade disputes and retaliatory actions; impairment of goodwill or intangible assets; the availability of and fluctuations in the cost of energy and raw materials; business or supply disruption, including in connection with the Previous Distributions; security threats, such as acts of sabotage, terrorism or war, natural disasters and weather events and patterns, disasters, public health issues, epidemics and pandemics, including COVID-19, or the fear of such events, and the inherent unpredictability, duration and severity of such events, which could result in a significant operational event for DuPont, N&B or IFF, adversely impact demand or production; ability to discover, develop and protect new technologies and to protect and enforce DuPont's, N&B's or IFF's intellectual property rights;, as well as management's response to any of the aforementioned factors. These risks, as well as other risks associated with the merger, are more fully discussed in the registration statement and proxy statement filed by IFF and the registration statement filed by N&B. While the list of factors presented here is, and the list of factors presented in registration statements filed by each of IFF and N&B in connection with the transaction, are considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Further lists and descriptions of risks and uncertainties can be found in IFF's annual report on Form 10-K for the year ended December 31, 2019, DuPont's annual report on Form 10-K for the year ended December 31, 2019, and each of IFF's and DuPont's respective subsequent reports on Form 10-Q, Form 10-K and Form 8-K, the contents of which are not incorporated by reference into, nor do they form part of, this announcement. Any other risks associated with the transaction are more fully discussed in the registration statements filed with the SEC. While the list of factors presented here is, and the list of factors presented in the registration statements, as amended, filed by each of IFF or N&B are representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on IFF's, DuPont's or N&B's consolidated financial condition, results of operations, credit rating or liquidity. None of IFF, DuPont nor N&B assumes any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.
有关交易的其他信息以及在哪里找到它
这种沟通不旨在且不得构成出售或征求要约或征求要约的要约，以便购买任何证券或征求任何批准的投票，也不应销售证券销售在任何此类管辖权的证券法下的登记或资格下，任何此类要约，请求或销售的任何司法管辖区都是非法的。除了拟议1933年“证券法”第10条（“证券法”）的“证券法”第10条规定的招股说明书，否则不得进行证券。与交易有关，N＆B向2020年12月31日的举行的招股说明书提交了载招名书的编写陈述陈述，IFF已向12月31日的招股说明书提出了关于S-4的注册声明，2020（共同，“注册陈述”）和杜邦向秒提交了一个计划。敦促投资者和安全持有人向这些文件中的注册报表，杜邦的进度和任何修正案或补充，以及在可用时提交的任何其他相关文件或者将其提交，因为它们将包含有关N＆B的重要信息，iff和dupont和交易。注册陈述，杜邦的时间表和与交易有关的其他文件（当它们可用时）也可以免费获得SEC网站的www.sec.gov．这些文件和每个公司的其他文件与SEC(可用时)也可以免费获得,杜邦和n和b,在书面请求我国LLC在美洲的1290大道,9号楼,纽约,纽约10104,或通过电话888-660-8331,或者,敌我识别,请向纽约10019 West 57 Street 521号的International flavor & Fragrances Inc.投资者关系部提出书面请求或致电(212)708-7164。
此外，对于任何有关交换要约的问题，一般您可以联系信息代理Georgeson LLC，电话888-660-8331。
查看原始内容以下载多媒体：http://www.prnewswire.com/news-releases/dupont-announces-final-results-of-exchange-offer-in-connection-with-frift-transaction-301220906.html.
源杜邦